Financials in USD. Standardized financial statements.
A compact view of how Legend Biotech Corporation turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $1.03B | $627.24M | $285.14M | $117.00M | $68.83M | $75.00M | $61.80M | $49.13M | $23.59M |
| Revenue Growth? | +64.0% | +120.0% | +143.7% | +70.0% | -8.2% | +21.4% | +25.8% | +108.2% | 0.0% |
| Cost of Revenue? | $408.10M | $234.58M | $144.21M | $65.36M | $0 | $0 | $0 | $0 | -$96,000 |
| Gross Profit? | $620.80M | $392.66M | $140.93M | $51.64M | $68.83M | $75.00M | $61.80M | $49.13M | $23.69M |
| Gross Margin? | +60.3% | +62.6% | +49.4% | +44.1% | +100.0% | +100.0% | +100.0% | +100.0% | +100.4% |
| Operating Expenses? | $757.30M | $695.90M | $580.41M | $507.26M | $461.11M | $75.00M | $194.31M | $64.20M | $9.60M |
| Operating Income? | -$136.50M | -$303.24M | -$439.49M | -$455.62M | -$392.29M | $0 | -$132.51M | -$1.53M | $13.78M |
| EBITDA? | -$232.30M | -$113.16M | -$477.87M | -$416.54M | -$392.38M | -$298.16M | -$129.35M | $149,000 | $14.06M |
| Income Before Tax | -$282.60M | -$158.13M | -$520.12M | -$445.72M | -$407.20M | -$308.29M | -$127.32M | -$1.62M | $13.84M |
| Income Tax Expense | $14.20M | $18.89M | -$1.86M | $625,000 | -$3.61M | -$41.91M | -$25.73M | $1.17M | $4.47M |
| Net Income? | -$296.80M | -$177.03M | -$518.25M | -$446.35M | -$403.58M | -$266.37M | -$101.59M | -$2.78M | $9.37M |
| EPS? | $-1.60 | $-0.97 | $-2.94 | $-2.81 | $-2.74 | $-2.57 | $-1.01 | $-0.03 | $0.07 |
| Diluted EPS? | $-1.60 | $-0.97 | $-2.94 | $-2.81 | $-2.74 | $-2.57 | $-1.01 | $-0.03 | $0.07 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality